• Ticker

DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$19.12 $0.10 (0.53%)

REAL-TIME: Last trade at

NuVasive, Inc.

NASDAQ:NUVA

RBC Capital to host a bus tour

Barclays' medical supplies and devices analysts hold a conference call

BofA/Merrill's medtech analyst research team holds a conference call

Barclays to host a bus tour

8 Stocks Surging on Big Volume

Canaccord Genuity Reiterates a 'Buy' on NuVasive (NUVA); Raising PT on Continued Growth Across All Business Segments

NuVasive gaps up after results, resistance is at $20.78

NuVasive upgraded to Outperform from Neutral at RW Baird

NuVasive upgraded to Outperform from Market Perform at William Blair

NuVasive sees FY12 EPS 93c, consensus 94c

NuVasive reports adjusted Q1 EPS 20c, consensus 18c

Nuvasive, Inc. (NUVA) Tops Q1 EPS by 2c; Reaffirms Outlook

NuVasive Reports First Quarter 2012 Financial Results

Biotechnology And Drugs Stocks To Watch For Next Week

NuVasive Announces Conference Call and Webcast of First Quarter 2012 Results

Piper Jaffray's medtech research team holds a conference call

Wells Fargo Starts NuVasive (NUVA) at Market Perform; Facing Market and Competitive Headwinds

NuVasive initiated with a Market Perform at Wells Fargo

NuVasive shares rise, resistance is now at $16.64

JMP Securities Upgrades NuVasive (NUVA) to Market Outperform

NuVasive upgraded to Outperform from Market Perform at JMP Securities

Goldman to host a bus tour

NuVasive to Participate in Investor Events in March 2012

NuVasive Has Been Bloodied, But The Growth Story Isn't Broken

Nuvasive Stock (NUVA): Stay On The Sidelines After Q4 Results And FY12 Outlook

NuVasive still facing risks, says Rodman & Renshaw

NuVasive downgraded at Craig-Hallum

NuVasive guidance achievable, risk/reward favorable, says Leerink

NuVasive poised to exceed 2012 guidance, says ThinkEquity

NuVasive downgraded to Hold from Buy at Craig-Hallum

NuVasive shares attractive at current levels, says Piper Jaffray

Nuvasive, Inc. (NUVA) Tops Q4 EPS by 5c, Sales Beat Expectations

NuVasive sees 2012 EPS 93c, consensus $1.02

NuVasive reports Q4 EPS 27c, consensus 22c

NuVasive Reports Fourth Quarter 2011 Financial Results

NuVasive outlook more positive following Medtronic comments, says Piper Jaffray

Baird Downgrades NuVasive (NUVA) to Neutral

NuVasive downgraded to Neutral from Outperform at RW Baird

Medtronic seeks interest payment and royalties from NuVasive, Bloomberg says

NuVasive Announces Conference Call and Webcast of Fourth Quarter and Full Year 2011 Results

See More Articles...